Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gotistobart + lutetium Lu 177 vipivotide tetraxetan
- Development stage
- Phase 2
- Lead developer
- OncoC4
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
This is a **combination drug** of gotistobart with lutetium Lu 177 vipivotide tetraxetan. Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent consisting of the radionuclide lutetium-177 linked to a ligand targeting prostate-specific membrane antigen (PSMA), a transmembrane protein overexpressed in prostate cancer cells. Once administered, the drug binds to PSMA-expressing cells and delivers beta radiation, causing DNA damage and cell death[1][2][5]. Gotistobart's identity and function are unclear from available sources; no evidence supports its use or mechanism, and it is not listed in recognized drug databases. The combination would, therefore, involve gotistobart plus a radiopharmaceutical agent approved primarily for PSMA-positive metastatic castration-resistant prostate cancer[1][2][3][5].
- Other names
- Pluvicto
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on gotistobart + lutetium Lu 177 vipivotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gotistobart + lutetium Lu 177 vipivotide tetraxetan.